Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
- Strong execution across pipeline of immune-modulating assets throughout 2020 enables multiple milestones in 2021 -- Rilonacept in recurrent pericarditis...